Coherus Oncology, Inc.

NASDAQ:CHRS

Biotechnology

Healthcare
$0.41 +1.80%

+$0.03 today

Market cap
$63.35M
Beta
0.96
P/E (TTM)
-1.3
EPS (TTM)
-$1.11
52W Low $0.71High $2.62

Volume 2.55M

Average 1.15M

CHRS Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Coherus Oncology, Inc.NASDAQ: CHRS

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 61.9%

Gross margin was 61.9% in Q1 FY2026, up 10.5 pp from a year earlier. On a trailing-twelve-month basis it was 60.0%, up 4.5 pp year over year. Over 3 fiscal years it narrowed by 8.9 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
61.9%+0.6 pp QoQ
Last fiscal yearDec 2025
57.9%+2.0 pp YoY
LTMMar 2026
60.0%+4.5 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+10.5 pp——
1 year+2.0 pp——
3 years-8.9 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
57.9%
Year-over-year change
+2.0pp

Gross Margin vs competitors

How CHRS compares with its peers on the latest reported figures

  • CHRS's LTM Mar 2026 gross margin of 60.0% is the 6th highest of the 9 companies compared; the peer median is 77.0%.
  • Its year-over-year change of +4.5 pp is the 4th highest of 9, against a peer median of -0.6 pp.
  • Over three fiscal years its change of -8.9 pp compares with a peer median of -8.3 pp.
CHRS Competitors Peer median
Gross Margin for CHRS and competitors
Company Period LTM level YoY 3-year change
SGMOSangamo Therapeutics, Inc.LTM Mar 2026100.0% +0.0 pp-8.3 pp
CCCCC4 Therapeutics, Inc.LTM Mar 202694.8% +9.6 pp-22.2 pp
IVVDInvivyd, Inc.LTM Mar 202692.0% -1.3 pp—
CDXSCodexis, Inc.LTM Mar 202683.9% +12.4 pp+14.2 pp
PLXProtalix BioTherapeutics, Inc.LTM Mar 202670.0% +20.0 pp-11.0 pp
CHRSCoherus Oncology, Inc.LTM Mar 202660.0% +4.5 pp-8.9 pp
OABIOmniAb, Inc.LTM Mar 202635.5% -64.5 pp-118.2 pp
IMDXInsight Molecular Diagnostics Inc.LTM Mar 202619.5% -33.1 pp+6.6 pp
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-17996.6% -16820.4 pp+19.0 pp
SLSSELLAS Life Sciences Group, Inc.FY2025— ——
TARAProtara Therapeutics, Inc.FY2025— ——
Peer median (excluding CHRS) 77.0%-0.6 pp-8.3 pp

Competitors are the stored peer set for CHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue326.55M211.04M257.24M266.96M42.17M
Cost of Revenue57.59M70.08M158.99M117.55M17.74M
Gross Profit268.96M140.96M98.25M149.41M24.43M
Gross Margin82.4%66.8%38.2%56.0%57.9%
Research & Development363.11M199.36M109.44M93.34M104.96M
Selling, General & Admin169.71M198.48M185.62M150.44M99M
Operating Expenses532.82M397.84M301.45M261.07M203.97M
Depreciation & Amortization3.45M3.7M3.79M5.28M3.92M
EBITDA(260.69M)(255.58M)(193.94M)60.94M(170.2M)
EBITDA Margin-79.8%-121.1%-75.4%22.8%-403.6%
Operating Income(263.86M)(256.88M)(203.2M)(111.67M)(179.53M)
Operating Margin-80.8%-121.7%-79.0%-41.8%-425.7%
Interest Income00000
Interest Expense22.96M32.47M40.54M27.16M9M
Other Income / Expenses(23.24M)(34.87M)(35.07M)140.17M(3.59M)
Income Before Tax(287.1M)(291.75M)(238.27M)28.51M(183.12M)
Pre-Tax Margin-87.9%-138.2%-92.6%10.7%-434.2%
Income Tax Expense00(380K)00
Net Income(287.1M)(291.75M)(237.89M)28.51M(170.29M)
Net Margin-87.9%-138.2%-92.5%10.7%-403.8%
EPS (Basic)(3.81)(3.76)(2.53)0.25(1.45)
EPS (Diluted)(3.81)(3.76)(2.53)0.25(1.45)
Weighted Avg Shares75.45M77.63M94.16M114.55M120.37M
Weighted Avg Shares (Diluted)75.45M77.63M94.16M114.83M120.37M

Coherus Oncology, Inc.

NASDAQ:CHRS

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.